Numinus to Participate in Wonderland: Miami on November 3-5, 2022

Rhea-AI Summary

Numinus Wellness Inc. (TSX: NUMI, OTCQX: NUMIF) announced its participation in the Wonderland conference in Miami from November 3-5, 2022. Dr. Reid Robison, Chief Clinical Officer, will present on the neurobiological differences between classic psychedelics and ketamine on November 5 at 9:50 a.m. ET. Numinus focuses on innovative mental health treatments, facilitating access to safe psychedelic-assisted therapies and aims to integrate these therapies into mainstream clinical practice, addressing conditions like depression and anxiety.

 VANCOUVER, BC, Oct. 31, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that it will participate in Wonderland: Miami hosted by Microdose to be held at the Mana Wynwood Convention Center in Miami, FL on November 3-5, 2022.

Dr. Reid Robison, MD MBA, Chief Clinical Officer of Numinus, will participate in the panel Neurobiological Mechanism Difference Between Classic Psychedelics and Ketamine on Saturday, November 5^th at 9:50 a.m. ET.

For more information about the conference, or to schedule a one-on-one meeting with Numinus' management, please send an email to KCSA Strategic Communications NuminusIR@kcsa.com.

About Numinus

Numinus Wellness (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic production, research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Learn more at www.numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.

Forward-looking statements

Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect" and "intend" and statements that an event "may", "will", "should", "could" or "might" occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. The Company does not undertake any obligation to update forward-looking statements even if circumstances or management's estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.

View original content:https://www.prnewswire.com/news-releases/numinus-to-participate-in-wonderland-miami-on-november-3-5-2022-301662907.html

SOURCE Numinus Wellness Inc.

FAQ

When is Numinus participating in the Wonderland conference?

Numinus is participating in the Wonderland conference from November 3-5, 2022.

Who is presenting for Numinus at the Wonderland conference?

Dr. Reid Robison, Chief Clinical Officer, will present for Numinus.

What is Dr. Robison's presentation topic at Wonderland?

Dr. Robison's presentation topic is the neurobiological mechanism difference between classic psychedelics and ketamine.

What does Numinus Wellness focus on?

Numinus focuses on developing innovative mental health care, specifically psychedelic-assisted therapies.

What are the stock symbols for Numinus?

Numinus is traded under TSX: NUMI and OTCQX: NUMIF.